NCT02486211View on ClinicalTrials.gov

Amantadine to Speed Awakening After Cardiac Arrest

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
ComaHeart ArrestAnoxia
Interventions
DRUG

Amantadine

100mg twice per day for 7 days at 0600 and 1200

DRUG

Placebo

Placebo comparator

Trial Locations (4)

15216

UPMC Presbyterian Hospital, Pittsburgh

15219

UPMC Mercy Hospital, Pittsburgh

04101

Main Medical Center, Portland

02215

Beth Israel Deacconness, Boston

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Jon Rittenberger, MD

OTHER

NCT02486211 - Amantadine to Speed Awakening After Cardiac Arrest | Biotech Hunter | Biotech Hunter